Tuesday, 9 December 2014
Exhibition Hall-Poster Area (Sul America)
Ali Kutlu, associated proff.
,
Allergy and Immunology, GATA Haydarpasa Teaching Hospital, Istanbul, Turkey
Ercan Karabacak, assistant Proff.
,
Dermatology, Gata Haydarpasa Teaching Hospital, Istanbul, Turkey
Ersin Aydın
,
Department of Dermatovenereology, Kasimpasa Military Hospital, Specialist in Dermatovenereology, İstanbul, Turkey
Sami Öztürk
,
Department of Allergy and Immunology, GATA Haydarpasa Teaching Hospital, Prof. Allergy and Immunology, Istanbul, Turkey
Bulent Bozkurt, ass.Prof
,
Department of Allergy and Immunology, Fatih University, Department of Allergy and Immunology, Fatih University, Ankara, Turkey
Background: A 24-year-old female patient was referred to our clinic because of allergic reactions history to almost every drug including steroids and antihistamines . During the follow-up period, the patient who had numerous urticarial angioedema attacks only after contact with detected allergens (drug or food) in general, began to experience spontaneous urticaria, angioedema attacks almost every day despite the fact that she paid excessive attention to the recommended diet formed by considering latex, nickel, salicylate allergies, and food sIgE values for the last 2 months.
Methods: Drugs provocation tests, Serum sIgE's and skin prict tests for some drugs and foods were performed
Results: Variable degrees of urticarial reactions against ciprofloxacin, amoxicillin, ceftideron, doxycycline, nimesulide, paracetamol, benzydamine, codeine, and sodium salicylate were observed. High serum IgE (sIgE) level was reported against ampicillin, amoxicillin, penicillin G, penicillin V, sulfamethoxazole, cephalosporin, tetracycline, and erythromycin (> 100 kU/L). Urticaria attacks raised after oral provocation tests administered with cetirizine (tablet and suspension formdesloratadine, and rupatadine. Shortness of breath, hoarseness, and short-term loss of consciousness were developed due to methylprednisolone injection,. Dexamethasone, deflazacort, and prednisolone allergy skin tests were also positive. Omalizumab treatment (300 mg per month) was administered.
Conclusions: Following the second dose, the patient started to see benefits of the treatment significantly, and after the third dose, this benefit has been maximized. The patient’s dermatological quality of life index was calculated to be 22 points before omalizumab administration and six points at the third month of the treatment
